JPWO2019044033A1 - Chemical supply device and water purification system using it - Google Patents

Abstract

The drug supply device (1) includes a membrane (6) through which the drug (8) can permeate and a membrane support portion (7) that supports the membrane (6), and is a drug storage unit that houses the drug (8). (2), the water supply unit (3) that supplies the water to be treated to the membrane (6), the water to be treated supplied from the water supply unit (3), and the drug (8) that has penetrated the membrane (6). It is provided with a mixing unit (4) for mixing the above and a discharging unit (5) for discharging the water to be treated mixed with the chemical (8).

Description

The present invention relates to a drug supply device and a water purification system. More specifically, the present invention relates to a drug supply device capable of supplying a fixed amount of a drug to water to be treated without using an expensive device such as a metering pump, and a water purification system using the same.

Generally, in water purification plants, water to be treated is taken from water sources such as rivers and reservoirs, and suspensions and colloids are removed from the water to be treated through unit processes of aggregation, floc formation, precipitation, filtration and disinfection ( For example, see Patent Document 1).

In recent years, various drug supply devices have been proposed as drug supply devices for purifying water to be treated. For example, Patent Document 1 proposes a coagulant storage tank, a coagulant transfer metering pump, a water supply device using treated water after purification treatment as a water supply source, an injector, and a coagulant injection device including a nozzle-mounted injection pipe.

Japanese Patent No. 5121983

In emerging countries where the social infrastructure is not well developed, there are many areas that do not have public water treatment facilities. In such areas, there is a need to purify water by installing water treatment equipment in each household. In particular, there is a need to remove turbid components such as metal ions and silica contained in the water to be treated by a water treatment device installed at home.

However, in the coagulant injection device as disclosed in Patent Document 1, it is premised that water is purified at a public water purification plant. The metering pump used in the coagulant injection device of Patent Document 1 is generally expensive, and it is difficult to apply it to a water treatment device installed at home.

The present invention has been made in view of the problems of the prior art. An object of the present invention is to provide a chemical supply device for supplying a fixed amount of chemicals to water to be treated and a water purification system using the same, without using an expensive device such as a metering pump.

In order to solve the above problems, the drug supply device according to the first aspect of the present invention includes a membrane through which the drug can permeate, a membrane support section for supporting the membrane, and a drug storage section for accommodating the drug. , A water supply unit that supplies water to be treated to the membrane, a mixing unit that mixes the water to be treated supplied from the water supply unit and a chemical that has penetrated the membrane, and discharges the water to be treated mixed with the chemical. It is equipped with a discharge unit.

Further, the water purification system according to the second aspect of the present invention is arranged in parallel with the drug supply device, the first bypass pipe provided with the drug supply device, and the first bypass pipe, with respect to the drug supply device. It is provided with a main pipe for connecting the pump arranged on the upstream side and the filtration device arranged on the downstream side with respect to the drug supply device.

FIG. 1 is a cross-sectional view showing an example of a drug supply device according to the first embodiment. FIG. 2 is a cross-sectional view showing an example of the drug supply device according to the second embodiment. FIG. 3 is a cross-sectional view showing an example of the drug supply device according to the third embodiment. FIG. 4 is a cross-sectional view showing an example of the drug supply device according to the fourth embodiment. FIG. 5 is a cross-sectional view showing an example of the drug supply device according to the fifth embodiment. FIG. 6 is a cross-sectional view showing an example of the drug supply device according to the sixth embodiment. FIG. 7 is a schematic view showing an example of the water purification system according to the first embodiment. FIG. 8 is a schematic view showing an example of the water purification system according to the second embodiment. FIG. 9 is a schematic view showing an example of the water purification system according to the third embodiment. FIG. 10 is a schematic view showing an example of the water purification system according to the fourth embodiment. FIG. 11 is a schematic view showing an example of the water purification system according to the fifth embodiment. FIG. 12 is a cross-sectional view of the drug supply device used in Example 1. FIG. 13 is a schematic view showing the configuration of the water purification system used in Example 1. FIG. 14 is a schematic diagram showing the configuration of the water purification system used in Comparative Example 1. FIG. 15 is a schematic diagram showing the configuration of the water purification system used in Comparative Example 2. FIG. 16 is a graph showing the relationship between the operating time and the turbidity of the water purified by the water purification systems of Examples and Comparative Examples.

Hereinafter, the drug supply device according to the present embodiment will be described in detail. The dimensional ratios in the drawings are exaggerated for convenience of explanation and may differ from the actual ratios. Further, in the present specification, water or rainwater pumped from a water source such as a well, a river or a pond whose water quality is improved by a water purification system is referred to as "water to be treated". The water to be treated, whose water quality is improved and purified, is called "purified water".

[Drug supply device 1]
The drug supply device 1 according to the present embodiment will be described with reference to the drug supply devices 1A to 1F according to the first to sixth embodiments, but the present embodiment is not limited to these embodiments. Absent.

(Embodiment 1)
The drug supply device 1A according to the present embodiment will be described with reference to FIG. The drug supply device 1A according to the present embodiment includes a drug storage unit 2, a water supply unit 3, a mixing unit 4, and a discharge unit 5.

Further, the drug supply device 1A of the present embodiment includes an outer accommodating portion 10. The outer accommodating unit 10 accommodates the drug accommodating unit 2, the water supply unit 3, and the mixing unit 4. The outer accommodating portion 10 includes a lid portion 10a, a side portion 10b, and a bottom portion 10c. The shape of the side portion 10b is not particularly limited, but in the present embodiment, it is formed in a substantially cylindrical shape, a bottom portion 10c is provided so as to cover one open portion, and the lid portion 10a can be removed from the other open portion. It is provided like this. Then, an introduction portion 11 for introducing the water to be treated and a discharge portion 5 for discharging the water to be treated to which the drug 8 is supplied are provided outside the outer accommodating portion 10 with respect to the bottom portion 10c.

The drug accommodating portion 2 includes a membrane 6 and a membrane support portion 7. Then, the drug storage unit 2 stores the drug 8. In the embodiment of FIG. 1, the agent 8 is housed in the space formed by the membrane 6 and the membrane support portion 7.

The film support portion 7 supports the film 6. In the first embodiment, the film support portion 7 is formed in a cylindrical shape, and the length of the side wall of the film support portion 7 is substantially the same at any position on the circumference. Then, the open portion at one end of the film support portion 7 is entirely covered with the film 6.

The membrane 6 is permeable to the drug 8. When the drug 8 permeates the membrane 6, the drug 8 is retained inside the membrane 6. Therefore, when the water to be treated is supplied to the membrane 6, the chemical 8 and the water to be treated come into contact with each other and are mixed. The membrane 6 is not particularly limited as long as the drug 8 can penetrate, but it is preferable that the membrane 6 has pores and the pore diameter of the pores is larger than the size of the molecule of the active ingredient contained in the drug 8. By setting the pore size of the membrane to such a size, an appropriate amount of the active ingredient contained in the drug 8 can be retained in the membrane 6. It is more preferable that the film 6 has pores and the pore diameter of the pores is 0.01 μm to 10 μm. By setting the pore size of the membrane 6 to 0.01 μm or more, the concentration of the drug 8 in the water to be treated can be quickly adjusted to an appropriate concentration. Further, by setting the pore size of the membrane 6 to 10 μm or less, it is possible to prevent the excess drug 8 from being supplied.

The material for forming the film 6 is not particularly limited, but may be at least one selected from the group consisting of ceramics such as cellulose acetate, polyacrylonitrile, polysulfone, polyethersulfone, polyethylene, polypropylene, polyvinylidene fluoride and alumina. preferable. Among these, cellulose acetate is preferable as the material for forming the film 6 from the viewpoints of ease of cleaning, flexibility, and ease of handling. Specific examples of the membrane 6 include an MF membrane (Microfiltration Membrane) and a UF membrane (Ultrafiltration Membrane).

The thickness of the film 6 is not particularly limited, but is preferably 1 μm to 100 μm. By setting the thickness of the film 6 to 1 μm or more, damage to the film can be suppressed. Further, by setting the thickness of the membrane 6 to 100 μm or less, the supply of the chemical 8 to the water to be treated can be facilitated.

The drug storage unit 2 is preferably removable from the drug supply device 1A. By making the drug storage unit 2 removable from the drug supply device 1A, the drug 8 can be replenished to the drug storage unit 2 outside the drug supply device 1A. Further, by making the drug storage unit 2 removable from the drug supply device 1A, a replacement drug storage unit 2 replenished with the drug 8 and a drug storage unit 2 in which the drug 8 is used and the remaining amount is low are used. Can be easily replaced with.

The agent 8 is not particularly limited as long as it contains an active ingredient that contributes to the treatment of the water to be treated. Examples of the agent 8 include an oxidizing agent and an aggregating agent.

The oxidant oxidizes the metal ions in the water to be treated. Specifically, it has an action of oxidizing divalent iron ions contained in the water to be treated into trivalent iron ions. Divalent iron ions are oxidized by oxygen in the air and gradually change to forms such as Fe (OH) ₃ and Fe ₂ O _{3 which} are difficult to dissolve in water, and may be precipitated in domestic water. Therefore, by adding an oxidizing agent to the water to be treated, divalent iron ions dissolved in water can be forcibly oxidized to trivalent iron ions to form a colloid that is difficult to dissolve in water. Although iron has been described as an example, the metal ions oxidized by the oxidizing agent are not limited to iron.

The oxidizing agent preferably contains ozone or chlorine because it can be easily added to the water to be treated and efficiently oxidizes metal ions. Among these, chlorine-based chemicals are preferable as the oxidizing agent. As the chlorinated agent, at least one selected from the group consisting of sodium hypochlorite, calcium hypochlorite and chlorinated isocyanuric acid can be used. As the calcium hypochlorite, at least one of bleaching powder (effective chlorine 30%) and highly bleaching powder (effective chlorine 70%) can be used. As the chlorinated isocyanuric acid, at least one selected from the group consisting of sodium trichloroisocyanurate, potassium trichloroisocyanurate, sodium dichloroisocyanurate, and potassium dichloroisocyanurate can be used. Among these, sodium hypochlorite is a liquid and can be quantitatively added to the water to be treated by using an injection method using a metering pump, so that it can be particularly preferably used. In addition, the inorganic highly bleached powder has extremely high solubility in water to be treated, so that it can exert a high oxidizing action.

The flocculant can aggregate colloids and the like formed by the oxidizing agent to form flocs. The formed flocs can be easily removed by a filtration device or the like. The coagulant is not particularly limited, and examples thereof include an aluminum-based coagulant and an iron-based coagulant. Examples of the aluminum-based flocculant include aluminum chloride and aluminum sulfate. Examples of the iron-based flocculant include ferrous sulfate (FeSO ₄ ), ferric sulfate (Fe ₂ (SO ₄ ) ₃ ), ferric chloride (FeCl ₃ ), and ferric polysulfate ([Fe _2). (OH) _n (SO ₄ ) _{3-n / 2} ] _m ), polysilica-iron flocculant ([SiO ₂ ] _n · [Fe ₂ O ₃ ]) and the like can be mentioned.

The state of the drug 8 is not particularly limited, and may be a solid drug or a liquid drug. Further, the shape of the solid drug is not particularly limited. Examples of the solid drug include tablets and granules.

In the case of a solid drug, the water to be treated supplied from the water supply unit 3 permeates the membrane 6 and dissolves the solid drug in contact with the membrane 6. The solid drug dissolved in the water to be treated is retained in the membrane 6 as a liquid drug containing the active ingredient. Then, when the water to be treated supplied from the water supply unit 3 comes into contact with the membrane 6, the chemical 8 and the water to be treated are mixed.

The water supply unit 3 supplies the water to be treated to the membrane 6. The water supply unit 3 is arranged on the opposite side of the membrane 6 from the drug 8. When the water to be treated is supplied to the membrane 6, the drug 8 held on the membrane 6 and the water to be treated come into contact with each other and are mixed. In the first embodiment, the water supply unit 3 is arranged so that the water to be treated is supplied to the substantially central portion in the radial direction of the drug storage unit 2 so that the amount of water to be treated that comes into contact with the membrane 6 is large. There is. The water supply unit 3 is connected to the bottom portion 10c at a substantially central portion in the radial direction of the mixing unit 4. The water supply unit 3 is not particularly limited as long as it can supply the water to be treated to the membrane 6, but for example, a nozzle or the like can be used.

The water supply unit 3 includes a supply port 3a, a side portion 3b, and a discharge port 3c. The side portion 3b is formed so that the introduction portion 11 and the water supply portion 3 communicate with each other via the supply port 3a. Then, the water to be treated introduced from the introduction unit 11 is discharged from the discharge port 3c through the supply port 3a, and the water to be treated is supplied to the membrane 6. In the first embodiment, the water supply unit 3 has a linear shape, but the shape of the water supply unit 3 is not particularly limited.

In the water supply section 3, the film 6 and the water supply section 3 are arranged with a gap in the thickness direction of the film 6. Further, although not particularly limited, the water supply unit 3 is arranged so that the thickness direction of the membrane 6 is substantially parallel to the supply direction of the water to be treated supplied from the water supply unit 3. The supply direction of the water to be treated here means the discharge direction of the water to be treated at the tip of the water supply unit 3. Further, substantially parallel here means that the thickness direction of the membrane 6 may be tilted by about ± 15 degrees with respect to the supply direction of the water to be treated supplied from the water supply unit 3.

The amount of water to be treated supplied from the water supply unit 3 is preferably the amount of water to be treated that can come into contact with the membrane 6. This is because the water to be treated and the drug 8 can be mixed in the mixing unit 4 by bringing the water to be treated into contact with the membrane 6. Specifically, it is preferable that the flow rate of the water to be treated has a linear velocity of 8 cm / s to 10 cm / s, and the gap between the tip of the water supply unit 3 on the membrane 6 side and the membrane is 5 mm to 10 mm. By setting the flow velocity of the water to be treated and the gap between the tip of the water supply unit 3 and the membrane 6 within the above ranges, the water to be treated is brought into contact with the membrane and the membrane 6 is prevented from being damaged by the water to be treated. Can be done.

It is preferable that a pedestal portion 9 smaller than the size of the membrane 6 is provided at the tip of the water supply portion 3 in the plane direction of the membrane 6. By providing such a pedestal portion 9, the water to be treated passed from the water supply portion 3 passes between the pedestal portion 9 and the membrane 6, so that the water to be treated is in contact with the membrane 6 for a long time. Can be maintained. Therefore, the supply amount of the chemical 8 to the water to be treated can be kept more constant. The distance between the top surface of the pedestal portion 9 and the bottom surface of the film 6 is preferably 2 mm to 10 mm. By setting the distance between the pedestal portion 9 and the membrane 6 in such a range, the membrane 6 and the water to be treated can be brought into contact with each other more stably. Further, the distance between the inner wall of the mixing portion 4 and the radial outer side of the pedestal portion 9 is preferably 2 mm to 10 mm. By setting the distance between the mixing portion 4 and the pedestal portion 9 in such a range, not only the water to be treated and the membrane 6 are in stable contact with each other, but also the water to be treated to which the chemical 8 is supplied is smoothed. Can be discharged to.

The pedestal portion 9 is provided with a hole in a substantially central portion in a cross-sectional view, and is connected to the tip of the water supply portion 3 so as to communicate with the water supply portion 3. The pedestal portion 9 is formed in a circular shape in a top view so as to extend outward from the hole at the substantially central portion in the cross-sectional view. Although not shown, the surface of the pedestal portion 9 may be provided with protrusions for supporting the film 6. By providing such a protrusion on the pedestal portion 9, the film 6 can be supported by the protrusion so that the film 6 does not sag.

The mixing unit 4 mixes the water to be treated supplied from the water supply unit 3 with the agent 8 that has penetrated the membrane 6. The shape of the mixing portion 4 is not particularly limited, but in the present embodiment, the mixing portion 4 has a substantially cylindrical shape, and the film 6 is arranged so as to be sandwiched between the membrane support portion 7 and the mixing portion 4. .. Further, in the present embodiment, the water supply unit 3 is arranged inside the mixing unit 4. Then, in the space formed by the mixing section 4 and the membrane 6, the water to be treated is supplied from the water supply section 3 to the membrane 6 in which the drug 8 is held, and the water to be treated and the drug 8 are mixed in the mixing section 4. .. After that, the water to be treated in which the drug 8 is mixed moves from the mixing unit 4 to the discharging unit 5.

The discharge unit 5 discharges the water to be treated mixed with the drug 8. The water to be treated containing the chemical 8 discharged from the discharge unit 5 is filtered by, for example, a filtration device, and is used by the user as domestic water. The discharge unit 5 may be provided with a drainage 12 for discharging the water to be treated accumulated in the discharge unit 5.

(Embodiment 2)
Next, the drug supply device 1B according to the second embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the drug supply device 1B according to the second embodiment, the thickness direction of the membrane 6 is inclined with respect to the supply direction of the water to be treated supplied from the water supply unit 3. That is, the thickness direction of the membrane 6 is arranged so as not to be parallel to the supply direction of the water to be treated supplied from the water supply unit 3. Specifically, the thickness direction of the film 6 is inclined with respect to the extension direction of the water supply unit 3.

By tilting the membrane 6 in this way, it is difficult for the membrane 6 to come into contact with the water to be treated above the point where the water to be treated comes into contact, but the water to be treated drips below the place where the water to be treated comes into contact. Easy to get wet and spread. Therefore, the contact area between the membrane 6 and the water to be treated can be easily changed by controlling the height at which the water to be treated is blown up and the flow velocity of the water to be treated. Specifically, by increasing the height at which the water to be treated is blown up, the contact area between the membrane 6 and the water to be treated can be increased. Further, if the height at which the water to be treated is blown up is lowered, the contact area between the membrane 6 and the water to be treated can be narrowed. Therefore, the concentration of the drug 8 in the water to be treated can be easily changed by a simple means of controlling the flow velocity of the water to be treated.

The thickness direction of the membrane is preferably inclined by 45 degrees to 89 degrees with respect to the supply direction of the water to be treated supplied from the water supply unit 3. By setting the inclination of the membrane 6 in such a range, it becomes easy to adjust the contact area between the membrane 6 and the water to be treated. The inclination of the membrane 6 does not exceed 89 degrees, and it is preferable that the inclination of the membrane 6 is large because the contact area between the membrane 6 and the water to be treated can be easily adjusted.

(Embodiment 3)
Next, the drug supply device 1C according to the third embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the drug supply device 1C according to the third embodiment, similarly to the second embodiment, the thickness direction of the membrane 6 is arranged so as to be inclined with respect to the supply direction of the water to be treated supplied from the water supply unit 3. Further, in the drug supply device 1C according to the third embodiment, the water supply unit 3 is arranged outside the substantially center in the radial direction of the mixing unit 4. Further, in the drug supply device 1C according to the third embodiment, the tip portion of the water supply portion 3 on the film 6 side is bent toward the radial center side of the mixing portion 4 to form the bent portion 3d.

As described above, in the drug supply device 1C according to the third embodiment, the tip portion of the water supply unit 3 is bent. Therefore, the contact area between the membrane 6 and the water to be treated can be changed by combining the tilt of the membrane 6 and the tilt due to the bending of the water supply unit 3, and the concentration of the drug 8 in the water to be treated can be controlled more finely. it can. Further, by bending the tip of the water supply unit 3 to adjust the positional relationship between the membrane 6 and the tip of the water supply unit 3 in the height direction, the contact area between the membrane 6 and the water to be treated can be easily increased. Can be changed. The angle of the bent portion 3d formed by bending the tip portion of the water supply portion 3 is preferably 135 degrees or more and less than 180. By setting the angle of the bent portion 3d in such a range, the height at which the water to be treated by the water supply portion 3 is blown up can be made sufficiently high, and the contact area between the membrane 6 and the water to be treated is widened. be able to. When the angle of the bent portion 3d is 180 degrees, it corresponds to the case where the water supply portion 3 is linear.

It is preferable that the tip of the water supply unit 3 is bent and the drug storage unit 2 is rotatably provided. By providing the drug accommodating portion 2 rotatably with respect to the drug supply device 1C, not only the height at which the water to be treated is blown up but also the drug accommodating portion 2 is rotated by a simple method, so that the membrane 6 and the water to be treated are rotated. The angle formed by the supply direction can be changed. Therefore, the contact area between the membrane 6 and the water to be treated can be controlled, and the concentration of the drug 8 supplied to the water to be treated can be controlled more easily and finely.

(Embodiment 4)
Next, the drug supply device 1D according to the fourth embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the fourth embodiment, similarly to the second and third embodiments, the thickness direction of the membrane 6 is inclined with respect to the supply direction of the water to be treated supplied from the water supply unit 3. However, in the fourth embodiment, a part of the drug accommodating portion 2 is accommodated inside the mixing portion 4.

Therefore, unlike the second embodiment, it is not necessary to change the lengths of the side walls of the drug accommodating portion 2 and the mixing portion 4 on the circumference, and the drug accommodating portion 2 and the mixing portion having an independent shape such as a columnar or rectangular parallelepiped are used. 4 can be used respectively. Then, even with such a simple configuration, the concentration of the drug 8 in the water to be treated can be adjusted by a simple means of controlling the flow velocity of the water to be treated, as in the second and third embodiments. It can be easily changed. Further, by providing the drug accommodating portion 2 so as to be rotatable, the concentration of the drug 8 supplied to the water to be treated can be controlled more easily and finely as in the third embodiment.

(Embodiment 5)
Next, the drug supply device 1E according to the fifth embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the drug supply device 1E according to the fifth embodiment, in the drug supply device 1D according to the fourth embodiment, the tip end portion of the water supply unit 3 is bent as in the third embodiment. Specifically, in the drug supply device 1E according to the fifth embodiment, the tip portion of the water supply portion 3 on the film 6 side is bent toward the radial center side of the mixing portion 4 to form the bent portion 3d.

By tilting the membrane 6 and the water supply unit 3, the contact area between the membrane 6 and the water to be treated is changed by combining the tilt of the membrane 6 and the tilt due to the bending of the water supply unit 3 as in the third embodiment. The concentration of the drug 8 in the water to be treated can be controlled more finely. Further, the contact area between the membrane 6 and the water to be treated can be easily changed by bending the tip of the water supply unit 3 and adjusting the positional relationship between the membrane 6 and the tip of the water supply unit 3 in the height direction. Can be done.

(Embodiment 6)
Next, the drug supply device 1F according to the sixth embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the drug supply device 1F according to the sixth embodiment, the entire lower surface of the membrane support portion 7 is not covered with the membrane 6, and only a part of the lower surface of the membrane support portion 7 is covered with the membrane 6. A bottom portion 2a through which the drug 8 does not penetrate is formed in a part of the membrane support portion 7 that is not covered with the film 6, so that the drug 8 cannot penetrate.

Then, since the inclination of the membrane 6 can be increased by tilting only a part of the membrane 6, the concentration of the chemical 8 in the water to be treated can be more easily adjusted by the ejection height of the water to be treated. it can. Further, by tilting only a part of the membrane 6, the amount of the drug 8 that can be stored in the drug storage unit 2 can also be increased.

As described above, the drug supply device according to the present embodiment includes a membrane through which the drug can permeate and a membrane support portion that supports the membrane, and supplies the drug storage portion that stores the drug and the water to be treated to the membrane. It is equipped with a water supply unit. Further, the drug supply device includes a mixing section that mixes the water to be treated supplied from the water supply section and the drug that has penetrated the membrane, and a discharging section that discharges the water to be treated mixed with the drug.

In the drug supply device according to the present embodiment, the water to be treated is supplied to the membrane through which the drug can permeate. Therefore, the chemical is supplied according to the flow rate of the water to be treated. Then, the water to be treated and the drug are mixed in the mixing portion. Therefore, the water to be treated and the drug are uniformly mixed at a constant concentration. Therefore, according to the drug supply device according to the present embodiment, the drug can be quantitatively mixed with the water to be treated with a simple configuration. Therefore, a fixed amount of chemical can be supplied to the water to be treated without using an expensive device such as a metering pump.

[Water purification system 100]
The water purification system 100 according to the present embodiment will be described with reference to the first to fifth embodiments, but the present embodiment is not limited to these embodiments.

(Embodiment 1)
First, the water purification system 100A according to the first embodiment will be described with reference to FIG. 7. The above-mentioned drug supply device 1 can be used for the water purification system 100A according to the present embodiment. By using such a drug supply device 1, a fixed amount of drug can be supplied to the water to be treated without using an expensive device such as a metering pump. Specifically, the water purification system 100A according to the present embodiment includes the chemical supply device 1, the first bypass pipe 132, and the main pipe 150.

As shown in FIG. 7, one of the main pipes 150 is submerged in well water, and the other is connected to a water tank inside the building. The main pipe 150 is provided with a pump 110 for pumping water to be treated (well water) from a well and a filtration device 140 for filtering turbid components contained in the water to be treated.

The main pipe 150 connects the pump 110 and the filtration device 140. Then, the water to be treated, which is pumped by the pump 110 and passes through the main pipe 150, passes through the filtration device 140 and is used by the user as domestic water.

The pump 110 is arranged upstream of the drug supply device 1. The pump 110 is not particularly limited as long as it can pump up the water to be treated and send it to the water purification system 100A. As the pump 110, for example, an automatic pump having a built-in pressure switch can be used.

As shown in FIG. 7, in the water purification system 100A, an oxidizing agent and a coagulant are added to the water to be treated which is pumped from the well water by the pump 110 and has passed through the main pipe 150, and the agglomerates are filtered by the filtration device 140. An example of filtering is shown. As shown in FIG. 7, the oxidant is supplied by the oxidant supply device 121, and the coagulant is supplied from the coagulant supply device 131. The drug supply device 1 may be an oxidant supply device 121, but in the present embodiment, an example in which the drug supply device 1 is a coagulant supply device 131 will be described.

The oxidant supply device 121 supplies the oxidant to the water to be treated. The oxidant supply device 121 is provided in the second bypass pipe 122. The main pipe 150 is arranged in parallel with the second bypass pipe 122. The upstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connection portion 123. Further, the downstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connecting portion 124. Then, a part of the water to be treated, which is pumped by the pump 110 and passes through the main pipe 150, passes through the second bypass pipe 122 via the connecting portion 123 and is supplied to the oxidant supply device 121. Then, the water to be treated to which the oxidant is supplied by the oxidant supply device 121 passes through the second bypass pipe 122 and returns to the main pipe 150 via the connection portion 124.

The coagulant supply device 131 supplies the coagulant to the water to be treated to which the oxidant has been supplied. As described above, in the present embodiment, the drug supply device is the coagulant supply device 131. The coagulant supply device 131 (drug supply device 1) is provided in the first bypass pipe 132. The main pipe 150 is arranged in parallel with the first bypass pipe 132. The coagulant supply device 131 supplies the coagulant to the water to be treated to which the oxidant has been supplied by the oxidant supply device 121. The flocculant is used to aggregate the metal components colloidalized by the action of the oxidizing agent. The upstream end of the first bypass pipe 132 is connected to the main pipe 150 at the connecting portion 133. The downstream end of the first bypass pipe 132 is connected to the main pipe 150 at the connecting portion 134. Then, the oxidizing agent is supplied, and a part of the water to be treated that passes through the main pipe 150 passes through the first bypass pipe 132 via the connecting portion 133 and is supplied to the coagulant supply device 131. Then, the water to be treated to which the coagulant has been supplied by the coagulant supply device 131 passes through the first bypass pipe 132 and returns to the main pipe 150 via the connecting portion 134.

In the coagulant supply device 131, the water to be treated is sent from the introduction unit 11 to the water supply unit 3 as described above. Then, the water to be treated is supplied from the water supply unit 3 to the membrane 6 of the drug storage unit 2, and is mixed with the flocculant (drug 8) in the mixing unit 4. Then, the water to be treated mixed with the coagulant is discharged from the discharge unit 5 and returns to the main pipe 150.

In the present embodiment, as described above, the coagulant supply device 131 is provided in the first bypass pipe 132. Therefore, for example, even when the fluctuation of the flow rate of the water used by the user becomes large, the fluctuation of the flow rate of the water to be treated passing through the coagulant supply device 131 is suppressed by the main pipe 150 and the first bypass pipe 132. can do. Therefore, the concentration of the drug 8 supplied to the water to be treated can be controlled to be more constant. In addition, fluctuations in the flow rate are suppressed, and the water to be treated with strong momentum is less likely to be supplied to the membrane 6, so that damage to the membrane 6 can also be suppressed. Further, since the fluctuation of the flow rate is suppressed, it is possible to prevent the air in the coagulant supply device 131 from being discharged to the outside by the force of the water flow and the inside of the coagulant supply device 131 being filled with the water to be treated. it can.

The pressure adjusting portion 125 may be provided inside the main pipe 150 between the connecting portion 123 and the connecting portion 124. Similarly, the pressure adjusting unit 135 may be provided inside the main pipe 150 between the connecting unit 133 and the connecting unit 134. The pressure adjusting unit 125 and the pressure adjusting unit 135 narrow the flow path through which the water to be treated passes to generate a water pressure difference before and after the pressure adjusting unit 125, thereby flowing through the second bypass pipe 122 and the first bypass pipe 132. The flow rate of treated water can be adjusted. The pressure adjusting unit 125 and the pressure adjusting unit 135 are not particularly limited as long as the flow rate of the water to be treated can be adjusted. As the pressure adjusting unit 125 and the pressure adjusting unit 135, an on-off valve, an orifice, a Venturi pipe and the like can be used, respectively.

The flow rate adjusting unit 126 and the flow rate adjusting unit 136 may be provided in the second bypass pipe 122 and the first bypass pipe 132, respectively. The flow rate adjusting unit 126 and the flow rate adjusting unit 136 can adjust the flow rate of the water to be treated flowing through the second bypass pipe 122 and the first bypass pipe 132. As the flow rate adjusting unit 126 and the flow rate adjusting unit 136, for example, an on-off valve can be used.

The filtration device 140 is arranged on the downstream side of the flocculant supply device 131 (drug supply device 1). The filtration device 140 can remove turbid components and the like aggregated by the water to be treated to which the coagulant is supplied, and can generate purified water to be used by the user. In the present embodiment, the filtration device 140 includes a sand filtration unit 141. The sand filtration unit can be formed of sand grains such as manganese sand. The density of manganese sand can be, for example, 2.57 g / cm ^{3 to} 2.67 g / cm ³ . The manganese adhesion amount of manganese sand is preferably 0.3 mg / g or more. However, the filtration device 140 may be formed of general filtration sand (2.5 g / cm ³ ).

(Embodiment 2)
Next, the water purification system 100B according to the second embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the second embodiment, the main pipe 150 is arranged in parallel with the first bypass pipe 132. Further, the main pipe 150 is arranged in parallel with the second bypass pipe 122. Further, the second bypass pipe 122 is arranged in parallel with the first bypass pipe 132.

The upstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connection portion 123. The downstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connecting portion 124. Further, the upstream end of the first bypass pipe 132 is connected to the upstream side of the oxidant supply device 121 in the second bypass pipe 122 at the connection portion 133. The downstream end of the first bypass pipe 132 is connected to the downstream side of the oxidant supply device 121 in the second bypass pipe 122 at the connection portion 134.

Then, a part of the water to be treated, which is pumped by the pump 110 and passes through the main pipe 150, is supplied to the second bypass pipe 122. Then, a part of the water to be treated that passes through the second bypass pipe 122 passes through the first bypass pipe 132 via the connecting portion 133 and is supplied to the coagulant supply device 131. The water to be treated to which the coagulant has been supplied by the coagulant supply device 131 passes through the first bypass pipe 132 and returns to the second bypass pipe 122 via the connecting portion 134.

On the other hand, a part of the water to be treated passing through the second bypass pipe 122 is supplied to the oxidizing agent supply device 121. The water to be treated to which the oxidant has been supplied merges with the water to be treated to which the coagulant has been supplied at the connection portion 134. In the second bypass pipe 122 downstream of the connecting portion 134, the water to be treated to which the oxidant is supplied and the water to be treated to which the coagulant is supplied are mixed and returned to the main pipe 150 via the connecting portion 124.

In the second embodiment, such an arrangement eliminates the need to use the two pressure adjusting units 135 used in the first embodiment. Therefore, it is possible to provide a water purification system having a lower manufacturing cost.

(Embodiment 3)
Next, the water purification system 100C according to the third embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the third embodiment, in addition to the second embodiment, a check valve 137 for preventing the backflow of the water to be treated is provided downstream of the coagulant supply device 131 in the first bypass pipe 132.

In the third embodiment, by providing such a check valve 137, the oxidant is contained even when the water to be treated flows in the direction opposite to the original flow direction due to the balance of the valve opening and the like. It is possible to prevent the water to be treated from flowing back into the coagulant supply device 131. Therefore, even when a material having low resistance to the oxidant is used for the film 6 of the coagulant supply device 131, it is possible to suppress the oxidative deterioration of the coagulant supply device 131. Further, even in the case where harmful chlorine gas or the like is generated when the oxidizing agent and the flocculant react with each other, the generation of such gas can be suppressed.

(Embodiment 4)
Next, the water purification system 100D according to the fourth embodiment will be described with reference to FIG. The same components as those in the first embodiment are designated by the same reference numerals, and redundant description will be omitted. In the fourth embodiment, the upstream side of the first bypass pipe 132 is connected to the second bypass pipe 122. Further, the downstream side of the first bypass pipe 132 is connected to the main pipe 150. Further, the downstream side of the second bypass pipe 122 is connected to the main pipe 150. The connection portion 124 between the downstream side of the first bypass pipe 132 and the main pipe 150 is arranged at a position different from the connection portion 134 between the downstream side of the second bypass pipe 122 and the main pipe 150.

Specifically, the upstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connecting portion 123. The downstream end of the second bypass pipe 122 is connected to the main pipe 150 at the connecting portion 124. Further, the upstream end of the first bypass pipe 132 is connected to the second bypass pipe 122 at the connection portion 133. The downstream end of the first bypass pipe 132 is connected to the main pipe 150 at the connecting portion 134.

In the fourth embodiment, the connection portion 124 between the downstream side of the first bypass pipe 132 and the main pipe 150 is connected at a position different from the connection portion 134 between the downstream side of the second bypass pipe 122 and the main pipe 150. .. Therefore, the coagulant is less likely to be mixed in the second bypass pipe 122, and the reaction between the oxidizing agent and the coagulant can be suppressed. Then, since such a side reaction is suppressed, the metal ions in the water to be treated can be sufficiently oxidized in the second bypass pipe 122.

It is preferable that the connection portion 124 between the downstream side of the first bypass pipe 132 and the main pipe 150 is arranged on the downstream side of the second bypass pipe 122 and the upstream side of the connection portion 134 between the main pipe 150. Metal ions in the water to be treated are more likely to be aggregated by the flocculant in the oxidized state. Therefore, with such an arrangement, the metal components that have been oxidized to become colloidal can be aggregated, and the efficiency of removing turbid components can be improved.

(Embodiment 5)
Next, the water purification system 100E according to the fifth embodiment will be described with reference to FIG. The same components as those in the above embodiment are designated by the same reference numerals, and duplicate description will be omitted. In the fifth embodiment, in addition to the fourth embodiment, a check flow prevention valve 137 for preventing the backflow of the water to be treated is provided downstream of the coagulant supply device 131 in the first bypass pipe 132.

In the fifth embodiment, by providing such a check valve 137, the water to be treated containing the oxidizing agent is a coagulant even when the water to be treated flows in the opposite direction due to the balance of the valve opening degree or the like. It is possible to prevent backflow to the supply device 131. Therefore, even when a material having low resistance to the oxidant is used for the film 6 of the coagulant supply device 131, it is possible to suppress the oxidative deterioration of the coagulant supply device 131. Further, even in the case where harmful chlorine gas or the like is generated when the oxidizing agent and the flocculant react with each other, the generation of such gas can be suppressed.

As described above, the water purification system according to the present embodiment includes the above-mentioned drug supply device and the first bypass pipe provided with the drug supply device. Further, the water purification system is arranged in parallel with the first bypass pipe and mainly connects the pump arranged on the upstream side with respect to the drug supply device and the filtration device arranged on the downstream side with respect to the drug supply device. Equipped with piping.

Therefore, for example, even when the flow rate of the water used by the user fluctuates greatly, it is possible to suppress the supply of an excessive amount of water to be treated to the drug supply device. Further, since the water purification system according to the present embodiment uses the chemical supply device according to the above embodiment, it is possible to supply a fixed amount of chemicals to the water to be treated without using an expensive device such as a metering pump. it can.

Hereinafter, the operation of the drug supply device in the present embodiment will be described in more detail with reference to Examples, but the present embodiment is not limited to these Examples.

[Example 1]
In Example 1, the coagulant supply device 231 (drug supply device) shown in FIG. 12 and the water purification system 200 shown in FIG. 13 were used to confirm the removal performance of turbid components.

As shown in FIG. 12, the coagulant supply device 231 has substantially the same configuration as the drug supply device 1A shown in FIG. 1 except that it does not have a pedestal portion. The height of the coagulant supply device 231 is 300 mm, and the inner diameter of the outer accommodating portion 60 is 125 mm. A coagulant supply device 231 is arranged inside the outer accommodating portion 60.

The coagulant supply device 231 includes a drug accommodating portion 52 having an inner diameter of 52 mm and a height of 100 mm, and the drug 58 is accommodated in the drug accommodating portion 52. As the agent 58, a liquid flocculant having a concentration of polyaluminum chloride of 11% was used. A membrane 56 is provided in the drug accommodating portion 52, and the average pore diameter of the pores of the membrane 56 is 0.45 μm.

A mixing portion 54 having a height of 100 mm is provided below the drug accommodating portion 52, and a water supply portion 53 having an inner diameter of 20 mm is provided inside the mixing portion 54. The water to be treated is supplied from the water supply unit 53 to the membrane 56 at a flow rate of 2.0 L / min, mixed with the coagulant in the mixing unit 54, and discharged from the discharge unit 55. The distance between the lower surface of the film 56 and the tip of the water supply unit 53 is 5 mm.

As shown in FIG. 13, the water purification system 200 includes a water storage tank 250 for storing water to be treated, an oxidant supply tank 221 for supplying an oxidant, a coagulant supply device 231 for supplying a coagulant, and a filtration device. It is equipped with 240 and. The water to be treated in the water storage tank 250 is sent by the supply pump 210 at a flow rate of 2.0 L / min.

The water to be treated is supplied to the coagulant supply device 231. A flow meter 255 for measuring the flow rate of the water to be treated is installed upstream of the supply pump 210. Kaolin is added to the water to be treated in the water storage tank 250 so that the turbidity becomes 100 NTU (Nephelometric Turbidity Unit).

The oxidant supply tank 221 is provided on the upstream side of the coagulant supply device 231 and on the downstream side of the supply pump 210, and the oxidant is used in the metering pump 228 so that the chlorine concentration of the water to be treated is 10 ppm. Is supplied.

The filtration device 240 is provided on the downstream side of the coagulant supply device 231. A cylindrical container having an inner diameter of 100 mm and a length of 715 mm is used for the filtration device 240. Inside the filtration device, 400 mL of activated carbon with a particle size of 20 x 50 mesh, 1800 mL of manganese sand with a particle size of 0.35 mm, and 500 mL of gravel with a particle size of 4 to 8 mm are laminated in this order from the upstream side. ..

[Comparative Example 1]
As shown in FIG. 14, a water purification system 300 was produced in the same manner as in Example 1 except that the flocculant supply device 231 was removed.

[Comparative Example 2]
As shown in FIG. 15, the water purification system is the same as in Example 1 except that the coagulant is supplied to the water to be treated by using the coagulant supply tank 239 and the metering pump 238 instead of the coagulant supply device 231. 400 was made.

[Evaluation]
By measuring the turbidity of the purified water obtained using the water purification system of each example, the removal performance of kaolin, which is a turbid component, was confirmed. The measurement result is shown in FIG. In the graph of FIG. 16, the vertical axis represents the turbidity of purified water, and the horizontal axis represents the operating time (minutes) of the water purification system.

As shown in FIG. 16, when the flocculant is not added, the turbidity cannot be sufficiently reduced as in the water purification system 300 of Comparative Example 1. On the other hand, the purified water obtained by the water purification system 200 of Example 1 was able to reduce the turbidity to the same level as the purified water obtained by the water purification system 400 of Comparative Example 2. Therefore, when the coagulant supply device 231 as in Example 1 was used, it was confirmed that a fixed amount of the chemical could be supplied to the water to be treated without using an expensive device such as a metering pump.

The entire contents of Japanese Patent Application No. 2017-163419 (Filing date: August 28, 2017) are incorporated herein by reference.

Although the contents of the present embodiment have been described above, it is obvious to those skilled in the art that the present embodiment is not limited to these descriptions and various modifications and improvements are possible.

According to the present invention, it is possible to obtain a chemical supply device capable of supplying a fixed amount of chemicals to water to be treated and a water purification system using the chemicals without using an expensive device such as a metering pump.

1,1A, 1B, 1C, 1D, 1E, 1F Drug supply device 2 Drug storage part 3 Water supply part 4 Mixing part 5 Discharge part 6 Membrane 7 Membrane support part 8 Drug 100, 100A, 100B, 100C, 100D, 100E Water Purification system 110 Pump 121 Oxidizing agent supply device 122 Second bypass pipe 131 Coagulant supply device (drug supply device)
132 First bypass pipe 137 Check valve 140 Filtration device 150 Main pipe

(Embodiment 4)
Next, the water purification system 100D according to the fourth embodiment will be described with reference to FIG. The same components as those in the first embodiment are designated by the same reference numerals, and redundant description will be omitted. In the fourth embodiment, the upstream side of the first bypass pipe 132 is connected to the second bypass pipe 122. Further, the downstream side of the first bypass pipe 132 is connected to the main pipe 150. Further, the downstream side of the second bypass pipe 122 is connected to the main pipe 150. The connection portion 134 between the downstream side of the first bypass pipe 132 and the main pipe 150 is arranged at a position different from the connection portion 124 between the downstream side of the second bypass pipe 122 and the main pipe 150.

In the fourth embodiment, the connection portion 134 between the downstream side of the first bypass pipe 132 and the main pipe 150 is connected at a position different from the connection portion 124 between the downstream side of the second bypass pipe 122 and the main pipe 150. .. Therefore, the coagulant is less likely to be mixed in the second bypass pipe 122, and the reaction between the oxidizing agent and the coagulant can be suppressed. Then, since such a side reaction is suppressed, the metal ions in the water to be treated can be sufficiently oxidized in the second bypass pipe 122.

It is preferable that the connection portion 134 between the downstream side of the first bypass pipe 132 and the main pipe 150 is arranged on the downstream side of the second bypass pipe 122 and on the downstream side of the connection portion 124 between the main pipe 150. Metal ions in the water to be treated are more likely to be aggregated by the flocculant in the oxidized state. Therefore, with such an arrangement, the metal components that have been oxidized to become colloidal can be aggregated, and the efficiency of removing turbid components can be improved.

Claims (13)

A drug accommodating portion that includes a membrane through which a drug can permeate and a membrane support portion that supports the membrane, and accommodates the drug.
A water supply unit that supplies water to be treated to the membrane,
A mixing unit that mixes the water to be treated supplied from the water supply unit with a drug that has penetrated the membrane.
A discharge unit that discharges the water to be treated mixed with the drug,
A drug supply device comprising. The drug supply device according to claim 1, wherein the membrane has pores, and the pore diameter of the pores is larger than the size of the molecule of the active ingredient contained in the drug. The drug supply device according to claim 1 or 2, wherein the membrane has pores and the pore diameter of the pores is 0.01 μm to 10 μm. The drug supply device according to any one of claims 1 to 3, wherein the amount of the water to be treated supplied from the water supply unit is the amount of water to be treated that can come into contact with the membrane. The drug supply device according to any one of claims 1 to 4, wherein the drug accommodating portion is removable. The drug supply device according to any one of claims 1 to 5, wherein a pedestal portion smaller than the size of the membrane in the plane direction of the membrane is provided at the tip of the water supply portion. The drug supply device according to any one of claims 1 to 6, wherein the thickness direction of the membrane is inclined with respect to the supply direction of the water to be treated supplied from the water supply unit. The drug supply device according to any one of claims 1 to 7, wherein the thickness direction of the membrane is inclined by 45 degrees to 89 degrees with respect to the supply direction of the water to be treated supplied from the water supply unit. The drug supply device according to any one of claims 1 to 8, wherein the tip end portion of the water supply unit is bent. The drug supply device according to any one of claims 1 to 9, wherein the tip end portion of the water supply section is bent and the drug storage section is rotatably provided. The drug supply device according to any one of claims 1 to 10.
The first bypass pipe provided with the drug supply device and
A main pipe arranged in parallel with the first bypass pipe and connecting a pump arranged on the upstream side with respect to the drug supply device and a filtration device arranged on the downstream side with respect to the drug supply device.
Water purification system equipped with. Further equipped with a second bypass pipe provided with an oxidant supply device for supplying the oxidant to the water to be treated.
The drug supply device is a coagulant supply device that supplies a coagulant to the water to be treated to which the oxidizing agent has been supplied.
The upstream side of the first bypass pipe is connected to the second bypass pipe.
The downstream side of the first bypass pipe is connected to the main pipe.
The downstream side of the second bypass pipe is connected to the main pipe.
The water purification according to claim 11, wherein the connection portion between the downstream side of the first bypass pipe and the main pipe is arranged at a position different from the connection portion between the downstream side of the second bypass pipe and the main pipe. system. Further equipped with a second bypass pipe provided with an oxidant supply device for supplying the oxidant to the water to be treated.
The drug supply device is a coagulant supply device that supplies a coagulant to the water to be treated to which the oxidizing agent has been supplied.
The second bypass pipe is arranged in parallel with the first bypass pipe.
The water purification system according to claim 11 or 12, wherein a check valve for preventing backflow of water to be treated is provided downstream of the coagulant supply device in the first bypass pipe.

Images